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ABSTRACT 
 
Introduction: To investigate the association between HLA-DRB1 alleles with 
susceptibility to rheumatoid arthritis (RA) and production of antibodies against 
citrullinated proteins (ACPA) and rheumatoid factor (RF). 
 
Methods: We studied 408 patients (235 with RA, 173 non-RA) and 269 
controls. ACPA, RF and HLA-DR typing were determined.  
 
Results: We found an increased frequency of HLA DRB1 alleles with the 
shared epitope (SE) in ACPA-positive RA. Inversely, HLA DRB1 alleles 
encoding DERAA sequences were more frequent in controls than in ACPA-
positive RA, and a similar trend was found for HLA DR3. However these results 
could not be confirmed after stratification for the presence of the SE, probably 
due to the relatively low number of patients. These data may suggest that the 
presence of these alleles may confer a protective role for ACPA-positive RA. 
In RA patients we observed association between SE alleles and ACPA titers in 
a dose-dependent effect. The presence of HLA DR3 or DERAA-encoding 
alleles was associated with markedly reduced ACPA levels. No association 
between RF titers and HLA DR3 or DERAA-encoding alleles was found. 
 
Conclusions: HLA DRB1 alleles with the SE are associated with production of 
ACPA. DERAA-encoding HLA-DR alleles and HLA DR3 may be protective for 
ACPA-positive RA. 
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INTRODUCTION 
 
Rheumatoid arthritis (RA) is a complex autoimmune disease that develops from 
the combined effects of genetic and environmental factors. It is estimated that 
the heritability of RA accounts for about 50–60%, and the most important 
genetic risk factors are the HLA class II molecules, which contribute to one-third 
of the total genetic susceptibility [1;2]. There is extensive evidence for the 
association between certain HLA-DRB1 alleles with a conserved amino acid 
sequence (Q/RK/RRAA) at residues 70 to 74 in the third hypervariable region of 
the DRβ1 chain, the so-called shared epitope (SE), and susceptibility to and 
severity of RA [3;4]. 
 
Autoimmunity in RA is characterized by the presence of autoantibodies. 
Rheumatoid factor (RF) is not specific to RA, as it may be present in other 
diseases and in healthy elderly individuals [5]. In contrast, anti–citrullinated 
protein antibodies (ACPA) seem to play a pivotal role in the pathogenesis of 
RA, as they are highly specific [6], can be detected years before the onset of 
symptoms [7;8], may predict progression to RA in patients with undifferentiated 
arthritis [9;10], are associated with the extent of joint destruction [11] and 
enhance disease severity in animal models of arthritis [12]. 
 
Recent studies, including our data, have demonstrated that SE alleles are 
associated only with ACPA-positive RA [13;14] and more strongly with ACPA 
than with RA itself [15], suggesting that SE alleles may influence antigen 
presentation pathways leading to ACPA production and have been used to 
subdivide patients into distinct immunopathogenetic disease classes [4]. While 
the association between ACPA-positive RA and SE-containing HLA class II 
molecules is well established, the association between HLA-DR protective 
versus non-predisposing alleles and ACPA-negative RA is controversial. 
Certain HLA-DR alleles may reduce the risk of developing RA and have been 
termed “protective alleles”; however, the definition of “protective alleles” differs 
depending on the study [16], making all of these results difficult to interpret. 
Alleles with the DERAA motif at positions 70–74 in the third hypervariable 
region have been associated with a reduced risk of RA susceptibility [17;18] and 
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less severe disease [17;19;20], while other studies have found conflicting 
results regarding HLA-DR3 [21-24]. 
 
Reproducing genetic associations is very important, and studies performed in 
cohorts outside of North America or Northwest Europe are especially welcome 
due to differences in allele frequencies and genetic background. To better 
understand the effect of HLA in RA in the Spanish population, we investigated 
the association of SE-containing HLA-DRB1 alleles with susceptibility to RA, 
and then we examined the possible protective effect of HLA-DR3 and DERAA-
encoding alleles. Finally, the effects of these alleles on the magnitudes of RF 
and ACPA production were determined. 
 
 
MATERIALS AND METHODS  
 
We studied 408 patients referred to the early arthritis clinic (EAC) of La Paz 
University Hospital, Madrid. Data from this cohort have been previously 
reported [14]. At enrollment or during follow-up, 235 patients fulfilled the 1987 
ACR criteria for RA, and 173 were diagnosed with non-rheumatoid arthritis 
(mainly undifferentiated arthritis, psoriatic arthritis, reactive arthritis and other 
connective tissue diseases) (Table 1). Most of the patients (91%) in the two 
groups have been followed up for more than 1 year (mean follow-up, 6.5 years). 
As controls, we included 269 healthy volunteers. The study was approved by 
the La Paz University Hospital ethics committee, and all subjects were of 
Spanish origin and provided written informed consent.   
 
For every patient, laboratory tests were performed on blood samples that were 
obtained during the patient’s first visit to the clinic, before treatment with 
disease-modifying antirheumatic drugs, and were stored at –40°C. Rheumatoid 
factor (RF) was measured by nephelometry (Behring, Nephelometer Analyzer 
II) with a detection limit of 15 U/ml, and ACPA were determined by a second-
generation anti-CCP-2 antibody ELISA (Immunoscan RA Mark 2; 
Eurodiagnostica, Arhem, The Netherlands) with a cut-off level of 25 arbitrary 
units/ml, according to the manufacturer’s instructions. The range of 
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measurement was 0–1600 U/ml, and all values higher than this upper limit were 
truncated and considered as 1600 U/ml for the analysis. 
 
In DNA samples obtained from peripheral blood of controls and cases, HLA 
class II alleles were genotyped using a reverse dot-blot kit with sequence-
specific oligonucleotide (SSO) probes (Dynal RELITM SSO HLA-DRB1 typing 
kit, Dynal Biotech, Bromborough, UK). When necessary, high-resolution typing 
of HLA-DRB1*03 samples was performed using Dynal AllSetTM SSP DRB1*03. 
The following alleles were considered SE-positive: DRB1*0101, *0102, *0401, 
*0404, *0405, *0408, *0410, *1001, *1402. DERAA-encoding alleles were HLA-
DRB1*0103, *0402, *1102, *1103, *1301, *1302 and *1304. 
 
Statistical analysis was performed using the Statistical Package for the Social 
Sciences version 10.0 (SPSS, Chicago, IL). Odds ratios (OR) and proportions 
were compared by the chi-square test.  Differences in values between groups 
were analyzed using Kruskal-Wallis and Mann-Whitney U tests for non-
parametric data. 
 
 
RESULTS 
 
Of the 253 patients with RA, 143 (61.9%) had ACPA and 169 (72.5%) RF 
(Table 1). The presence of both autoantibodies was strongly associated with RA 
(OR 27.4, 95% confidence interval (CI) 14.08–53.34, p<0.001 and OR 14.99, 
95% CI 9.18–24.45, p<0.001, respectively). In non-RA patients, only 9 (5.6%) 
and 27 (15.9%) had ACPA and RF, respectively (Table 1). Double positivity for 
both ACPA and RF were found in 137 (59.3%) RA patients and in 6 (3.5%) 
patients with other arthropathies. 
 
The distribution of our study population with respect to HLA-DRB1 genotypes 
and alleles is shown in Tables 2 and 3. As described previously, an increased 
frequency of HLA-DRB1 alleles encoding the SE was found in patients with RA 
compared with non-RA and control subjects (56.2% vs. 35.5%, OR 2.33, 95% 
CI 1.56–3.5, p<0.001 and 56.2% vs. 41.6%, OR 1.8, 95% CI 1.26–2.56, 
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p=0.001, respectively). There was a dose-dependent effect of SE-encoding 
HLA-DRB1 alleles: 29.8% of RA cases and 24.9% of controls had one allele 
(OR 1.89, 95% CI 1.13–3.13), while 14% of RA cases and 5.6% of controls 
were homozygous for SE-encoding HLA-DRB1 alleles (OR 3.97, 95% CI 1.93–
8.16) (Table 3). 
 
The frequency of HLA-DR3 alleles was lower in the RA than in the non-RA 
group (18.3% vs. 28.3%, OR 0.57, 95% CI 0.36–0.90, p= 0.012) but similar to 
the healthy controls (18.3% and 19.7%, respectively). No differences in the 
DERAA-encoding allele distribution were found among the three groups (RA 
23.4%, non-RA 26.6% and controls 26.8%, p=0.39). Next, we studied the effect 
of the presence of HLA-DR3 or DERAA-encoding alleles in combination with the 
SE on susceptibility to RA. In the presence of one SE allele, a HLA-DR3 or 
DERAA-encoding allele reduced the risk of developing RA, although the effect 
was not statically significant (OR 1.11, 95% CI 0.51–2.43 for HLA-DR3 and OR 
1.04, 95% CI 0.46–2.36 for DERAA-encoding alleles) (Table 3). Finally, to study 
the effect of the presence of HLA-DR3 or DERAA-encoding alleles on 
susceptibility, we combined homozygous and heterozygous patients and 
controls for these alleles and compared them with “neutral” alleles. No 
differences in susceptibility were found for HLA-DR3 (OR  1.53, 95% CI 0.76–
3.04) or DERAA-encoding alleles (OR  1.33, 95% CI 0.74–2.39). 
 
To investigate whether HLA-DR alleles were associated with different RA 
phenotypes,  we divided our RA population according to ACPA status (Table 4). 
We found a higher frequency of SE alleles in ACPA-positive RA compared with 
healthy controls (67.8% vs. 41.6%, OR 2.95, CI 1.93–4.53, p<0.001), but we did 
not observe this relationship with ACPA-negative RA patients and controls 
(35.2% vs. 41.6%, p=0.31), indicating that SE alleles are associated with ACPA 
production in RA. Inversely, HLA-DRB1 alleles encoding the DERAA sequence 
were more frequent in controls than in ACPA-positive RA patients (26.8% vs. 
17.5%, OR 0.58, CI 0.34–0.96, p=0.03), and a similar trend was found for HLA-
DR3 (19.7% vs. 12.6%, OR 0.32–1.04, p=0.07). However, the frequency of 
HLA-DR3 was similar in controls and ACPA-negative RA patients, indicating 
that the presence of these alleles confers a protective role only for ACPA-
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positive RA. To further investigate whether, in ACPA-positive RA patients, the 
decreased frequencies of DERAA and HLA-DR3 alleles were secondary to the 
increased frequencies of SE, we stratified our study population by the presence 
of SE. Only a trend was observed for HLA DR3, and no effect was observed for 
DERAA-encoding alleles, probably because of the low numbers of patients 
remaining (Table 5). No effect on RF of HLA-DR3 (OR 1.10, 95% CI 0.43–2.83, 
p=0.8) or DERAA-encoding alleles (OR  0.78, 95% CI 0.28–2.15 p=0.5) was 
observed. 
 
In RA patients, we observed a dose-dependent association between the 
presence of SE alleles and titers of RF and ACPA (Figure 1). With two SE 
alleles, ACPA had a median value of 915 Au/ml in our ELISA, with an 
interquartilic range (IR) of 124–1500. With one SE allele, there was a median 
ACPA of 400 (0–1050), and with no alleles it was 0 (0–650; p<0.001). The 
presence of HLA-DR3 or DERAA-encoding alleles was associated with 
markedly reduced ACPA levels. In the presence of HLA-DR3, ACPA had a 
median value of 0 (0–594), while in the absence of HLA-DR3, ACPA had a 
median value of 360 (0–1000) (p=0.002). ACPA was 0 (0–653) in the presence 
of DERAA-encoding alleles vs. 310 (0–1000) in the absence of any DERAA-
encoding alleles (p=0.013). No association between RF titers and HLA-DR3 or 
DERAA-encoding alleles was found.  
 
Next, we investigated the influence of DERAA-encoding alleles or HLA-DR3 
together with one SE allele on RF and ACPA production. Although ACPA levels 
were lower in the presence of HLA-DR3 or DERAA alleles in combination with 
one SE allele (SE/DR3 or SE/DERAA) than in HLA-DR SE/– patients, these 
differences were not statistically significant (median 500 IQR (34–1250) in SE/– 
vs. 468 (0–760) in SE/DERAA and 32 (0–900), p=0.11. No similar trend for  RF 
was found (Figure 2). 
 
 
DISCUSSION 
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Since Gregersen et al. formulated the SE hypothesis in 1987 [25], several 
authors have investigated the relationship between RA and SE-encoding HLA 
DRB1 alleles. An important discovery is that these alleles are associated with 
ACPA in RA, irrespective of RF status [26]. Moreover, it has recently been 
demonstrated that SE alleles are not associated with RA but are specific for a 
disease characterized by ACPA [27]. Our results confirm these observations, as 
ACPA-positive RA was strongly associated with the SE, with a gene-dose 
effect. 
 
It was proposed that SE alleles function as immune response genes in the 
development of ACPA, as no differences in ACPA levels were found between 
RA patients with one or two SE copies [15]. In our cohort, as in other studies, a 
risk hierarchy in ACPA production with a significant dose effect in patients with 
two predisposing alleles was found [23]. Some frequent SE alleles in Northern 
Europe, such as DRB1*0401 and *0404, appear to confer a much greater 
degree of risk for RA [28-30] and are associated with higher levels of ACPA 
than the DR1 or DR10 alleles are [29;30]. We have reported that in our Spanish 
inception cohort, DR1 and DR4 alleles with the SE are equally represented [31], 
and DR10 is a frequent SE allele in the Spanish population [32]. Therefore, it is 
possible that DR1- and/or DR10-heterozygous patients have lower levels of 
ACPA than DR4 patients and that DR1- and/or DR10-homozygous patients 
have higher levels of ACPA.  
 
A lack of association between ACPA and SE alleles, when they were analyzed 
together, has been described, with 68% of SE-negative patients having ACPA, 
compared to 32% in our cohort [30]. One reason for the lack of association may 
be the influence of external risk factors. Tobacco exposure is a well-known 
environmental risk factor for the development of ACPA in the presence of SE 
alleles [33] but also in their absence [34]. Increased ACPA levels in tobacco 
users have been reported, but these effects were only relevant for DR1 and 
DR10 alleles, with no significant effect on DR4 patients who had higher levels 
regardless of tobacco exposure [29]. Other reasons may be that not only 
inherited SE alleles but also non-inherited SE alleles from the mother (NIMA) 
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can be associated with RA susceptibility [35], and SE-positive cells persist in 
SE-negative women as a consequence of pregnancy (microchimerism) [36]. 
 
There are no well-established genetic risk factors for ACPA-negative RA [4]. 
Two studies have reported an increased risk of ACPA-negative RA associated 
with the presence of HLA-DR3 [21;22]; however, our results, as those of two 
independent groups [23;24], do not support that finding. Instead, in HLA-DR3 
carriers, we have only found a reduced risk of ACPA-positive RA. Another 
interesting finding of our study is that, as reported previously [21], HLA-DR3 
carriers had lower levels of ACPA compared with DR3 non-carriers. As this 
result may have been due to the reduced risk of ACPA production, we further 
analyzed the effect of HLA-DR3 in the presence of one SE allele and found a 
reduction in ACPA levels. The fact that we did not observe levels above the 
upper limit of detection of our ELISA may limit our capacity to demonstrate 
statistically significant differences. 
 
The higher frequency of HLA-DR3 found in non-rheumatoid arthritis patients in 
our cohort was not unexpected. HLA-DR3 has been associated with several 
autoimmune diseases and with autoantibody production, mainly as a part of an 
extended haplotype designated A1;B8;DR3 [37;38]. Whether the association 
with autoimmune diseases is caused by HLA-DR3 itself or by other nearby 
genes in linkage disequilibrium remains to be determined [21].   
 
It has been proposed that some HLA class II alleles with a neutral or negative 
electric charge in their P4 pocket, such as DERAA-encoding alleles, reduce the 
risk of developing RA [17;23;39]; however, while the RA shared epitope is 
consistently and reproducibly associated with RA in Caucasians, the 
“protective” effect of some HLA alleles is far from fully accepted [16]. Our results 
are in accord with recent reports [28] and do not confirm that hypothesis. As 
with HLA-DR3, HLA DERAA-encoding alleles were only associated with a 
reduced risk of ACPA-positive RA, but this effect disappeared after stratification 
for the presence of the SE. As these same alleles have been associated with a 
reduced risk of RA [17;18], it is possible that these results are due to the low 
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number of patients remaining after stratification, and new studies including 
greater numbers of patients are needed to clarify this effect.   
 
HLA-DR3 and HLA DERAA-encoding alleles were associated with lower levels 
of ACPA, and this finding may explain the association with less severe disease 
[19;20]. The progression of joint damage has been related to levels of ACPA, 
both in RA patients [40;41] and in animal models of arthritis [12], so the 
previously described less severe disease in DERAA allele carriers may be due 
to lower levels of ACPA. The reason for the reduced levels of ACPA in the 
presence of HLA-DR3 or DERAA-encoding alleles is not clear, but it has been 
suggested that some non-associated MHC class II molecules may contain P4 
pockets that lack the proper size or charge to effectively accommodate the large 
polar side chains of citrulline, and they would be unable to bind to and present 
modified citrullinated peptides [42;43].  
 
Overall, our data confirm the considerable complexity of HLA class II 
associations with RA. Many of the previously reported inconsistencies may be 
due not only to genetic differences or the influence of other genes in linkage 
disequilibrium but to the interaction with environmental risk factors. In summary, 
in this study confirmed the previously reported observation that ACPA-positive 
RA is strongly associated with the SE, with a gene-dose effect in a Spanish 
population. However, our results do not support the hypothesis that HLA-DR3 or 
DERAA-encoding alleles protect against RA or are associated with ACPA-
negative RA, but rather they only reduce the risk of ACPA-positive RA.  
 
CONCLUSIONS  
In this study, we have examined the relationship between HLA-DRB1 alleles 
and RA in an inception cohort of early arthritis patients, and we confirm previous 
evidence of an association between SE-containing HLA-DRB1 alleles and 
ACPA-positive RA. Our results do not support a protective effect of HLA-DR3 or 
DERAA-encoding alleles against RA, nor are these alleles associated with 
ACPA-negative RA in the Spanish population. Instead, we suggest that these 
alleles reduce the risk of ACPA-positive RA, but these results must be 
confirmed with higher number of patients or by analyzing pooled data from 
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reported cohorts. The presence of theses alleles was associated with lower 
levels of ACPA antibodies, but in the presence of one SE allele, this interaction 
could not be demonstrated. 
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Table 1. Baseline characteristics of the patients in the study 
 RA (n=253) Non-RA (n=173) 
Age (mean ± SD) 62 ± 12 50 ± 14 
Women, % 64 55 
ACPA positive 143 (61.9%) 9 (5.6%) 
RF positive 169 (72.5%) 27 (15.9%) 
Duration of symptoms, median (range) weeks 20 (3–52) 15 (2–52) 
RA = rheumatoid arthritis; Non-RA = other arthropathies; RF = IgM rheumatoid factor; 
ACPA = anti–citrullinated protein antibodies. 
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Table 2.  Distribution of HLA-DRB1 alleles in the study population. Number and 
percent of patients in each group   
 
 RA 
(235 patients) 
Non-RA 
(173 patients) 
Controls 
(n=269) 
*0101 49 (10.4%) 15 (4.3%) 32 (5.9%) 
*0102 17 (3.6%) 13 (3.7) 16 (3.0%) 
*0401 27 (5.7%) 10 (2.9%) 23 (4.3%) 
*0404 19 (4%) 7 (2.0%) 10 (1.8%) 
*0405 27 (5.7%) 9 (2.6%) 17 (3.1%) 
*0408 4 (0.8%) 5 (1.4%) 8 (1.5%) 
*1001 18 (3.8%) 7 (2.0%) 18 (3.3%) 
SE 
*1402 4 (0.8%) 2 (0.6%) 3 (0.5%) 
DR3 *03 43 (9.1%) 54 (15.6%) 55 (10.2%) 
*0103 4 (0.8%) 9 (2.6%) 14 (2.6%) 
*0402 7 (1.5%) 6 (1.7%) 10 (1.8%) 
*1102 6 (1.3%) 5 (1.4%) 11 (2.0%) 
*1103 7 (1.5%) 7 (2.0%) 12 (2.3%) 
*1301 25 (5.3%) 20 (5.8%) 27 (5.0%) 
*1302 11 (2.3%) 1 (0.3%) 5 (0.9%) 
DERAA 
*1304 - - - 
 
RA = rheumatoid arthritis; Non-RA = other arthropathies; SE = shared epitope alleles; 
DERAA = HLA with DERAA-encoding alleles. 
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Table 3.  Distribution of HLA-DRB1 genotypes 
RA 
(235 patients) 
Non-RA 
 (n=173) 
Controls 
(n=269) 
 
Number % Number % Number % 
SE/SE 33 14.0 7 4.0 15 5.6 
SE/– 70 29.8 31 17.9 67 24.9 
SE/DR3 15 6.4 12 6.9 16 5.9 
DR3/– 21 8.9 25 14.4 23 8.6 
DR3/DR3 - - 5 2.9 2 0.7 
SE/DERAA 14 6.0 11 6.3 14 5.2 
DERAA/– 29 12.3 26 15.0 39 14.5 
DERAA/DERAA 5 2.1 2 1.1 7 2.6 
DR3/DERAA 7 3.0 7 4.0 12 4.5 
No alleles (–/–) 41 17.4 47 27.1 74 27.5 
 
RA = rheumatoid arthritis; Non-RA = other arthropathies; SE = shared 
epitope alleles; DR3 = HLA-DR3; DERAA = HLA with DERAA-encoding 
alleles. 
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Table 4. Association of HLA-DRB1 alleles with the SE, HLA-DR3 and DERAA motif 
with ACPA-positive or ACPA-negative RA 
Controls 
(n=269) 
 
RA patients 
(n=231) 
 
 
ACPA+ (n=143) 
 
ACPA– (n=88) 
 
 
  
 p OR  (95% CI)  p 
OR  
(95% CI) 
absence n (%) 157 (58.4) 46 (32.2) 57 (64.8) 
SE 
presence n (%) 112 (41.6) 97 (67.8) 
0.0001 2.95  (1.93–4.53) 
  
31 (35.2) 
0,31 0.76 (0.46–1.27) 
    
absence n (%) 216 (80.3) 125 (87.4) 63 (71.6) 
DR3 
presence n (%) 53 (19.7) 18 (12.6) 
0.07 0.58  (0.32–1.04) 
  
25 (28.4) 
0,10 1.61  (0.93–2.80) 
  
     
absence n (%) 197 (73.2) 118 (82.5) 58 (65.9) 
DERAA 
presence n (%) 72 (26.8) 25 (17.5) 
0.03 0.58 (0.34–0.64) 
30 (34.1) 
0,22 1.41  
(0.84–2.37) 
  
RA = rheumatoid arthritis; SE = shared epitope allele; DR3 = HLA-DR3; DERAA = 
DERAA-encoding allele; ACPA = anti–citrullinated protein antibodies. 
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Table 5. Association of HLA-DR3 and DERAA-encoding alleles stratified by the 
presence of shared epitope alleles with ACPA-positive RA 
Controls 
(n=269) 
 
ACPA-positive RA patients 
(n=143) 
 
 
 
 p OR  (95% CI) 
DR3-positive 16 (14.3) 8 (8.2) 
SE-positive 
DR3-negative 96 (85.7) 89 (91.8) 
0.17 0.53  (0.22–1.22) 
  
DR3-positive 37  (23.6) 10 (21.7) 
SE-negative 
DR3-negative 120 (76.4) 36 (78.3) 
0.84 0.90  (0.40–1.98) 
  
DERAA-positive 14 (12.5) 10 (10.3) 
SE-positive 
DERAA-negative 98 (87.5) 87 (89.7) 
0.85 0.58 (0.34–1.90) 
DERAA-positive 58 (36.9) 15 (32.6) 
SE-negative 
DERAA-negative 99 (63.1) 31 (67.4) 
0.72 0.82 (0.41–1.65) 
RA = rheumatoid arthritis; SE = shared epitope allele; DR3 = HLA-DR3; DERAA 
= DERAA-encoding allele; ACPA = anti–citrullinated protein antibody. 
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Figure 1. Box plots of ACPA levels (a) in arbitrary units and rheumatoid factor 
(b) in UI/ml in rheumatoid arthritis patients depending on the number of shared 
epitope alleles. Each box represents the 25th to 75th percentiles. Lines outside 
the boxes represent the 10th and 90th percentiles. Lines inside the boxes 
represent medians. Differences in values between groups were analyzed using 
the Kruskal-Wallis test for non-parametric data. 
 
Figure 2. Box plots of ACPA levels (a) in arbitrary units and rheumatoid factor 
(b) in UI/ml in rheumatoid arthritis patients depending on the presence of one 
shared epitope allele combined with a HLA-DR3 or DERAA-encoding allele. 
Each box represents the 25th to 75th percentiles. Lines outside the boxes 
represent the 10th and the 90th percentiles. Lines inside the boxes represent 
medians. Differences in values between groups were analyzed using Kruskal-
Wallis test for non-parametric data. N.S., not significant. 
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